Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (68)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aboulghar, M.A.
Right arrow Articles by Mansour, R.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aboulghar, M.A.
Right arrow Articles by Mansour, R.T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction Update, Vol.9, No.3 pp.275-289, 2003
© European Society of Human Reproduction and Embryology 2003; all rights reserved

Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures

M.A. Aboulghar1 and R.T. Mansour1

1 The Egyptian IVF-ET Center, Maadi, Cairo, Egypt

To whom correspondence should be addressed at: M.A. Aboulghar, The Egyptian IVF-ET Center, 3, 161 St, Hadayek Al Maadi, 11431, Cairo, Egypt. e-mail: ivf{at}link.net

Abstract

The aim of this review was to summarize previously published classifications for ovarian hyperstimulation syndrome (OHSS), as well as to analyse the available methods for preventing OHSS. Withholding hCG and cycle cancellation—once the main methods of preventing OHSS—are now seldom used. There is a growing body of evidence to support the use of coasting to prevent OHSS, without cycle cancellation. However, most studies on coasting are retrospective, and well-designed prospective randomized studies are lacking. There is no current consensus as to how coasting should be carried out. A serum estradiol level of 3000 pg/ml is generally considered optimum for administration of hCG. It appears that intravenous albumin or hydroxyethyl starch at the time of oocyte retrieval is beneficial in preventing OHSS, but does not offer complete protection. There is insufficient evidence to support routine cryopreservation of all embryos for the later transfer of frozen–thawed embryos in high-risk patients. Several uncontrolled studies have reported the protective effect of GnRH agonist to trigger ovulation in preventing OHSS, though the method is applicable solely for gonadotrophin-only or GnRH antagonist cycles. A single dose of recombinant LH to trigger ovulation significantly reduced OHSS as compared with hCG. The possible role of GnRH antagonist protocols in reducing the incidence of OHSS is debatable. The above measures to prevent OHSS were successful in reducing the incidence of the syndrome, but complete prevention is not as yet possible.

Key words: classification / coasting / intravenous albumin / OHSS / prevention


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
P. A. Vardhana, M. A. Julius, S. V. Pollak, E. G. Lustbader, R. K. Trousdale, and J. W. Lustbader
A Unique Human Chorionic Gonadotropin Antagonist Suppresses Ovarian Hyperstimulation Syndrome in Rats
Endocrinology, August 1, 2009; 150(8): 3807 - 3814.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
P. Devroey, B.C.J.M. Fauser, K. Diedrich, and on behalf of the Evian Annual Reproduction (EVAR)
Approaches to improve the diagnosis and management of infertility
Hum. Reprod. Update, July 1, 2009; 15(4): 391 - 408.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Devroey, M. Aboulghar, J. Garcia-Velasco, G. Griesinger, P. Humaidan, E. Kolibianakis, W. Ledger, C. Tomas, and B. C.J.M. Fauser
Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment
Hum. Reprod., April 1, 2009; 24(4): 764 - 774.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser
Mild ovarian stimulation for IVF
Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
B.C.J.M. Fauser, K. Diedrich, P. Devroey, and on behalf of the Evian Annual Reproduction (EVAR)
Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation
Hum. Reprod. Update, January 1, 2008; 14(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study
Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. Aboulghar
Preventing Ovarian Hyperstimulation Syndrome
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2882 - 2884.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simon, and A. Pellicer
Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2931 - 2937.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
D M Raw and M C Collins
Internal jugular vein thrombosis and ovarian hyperstimulation syndrome
J R Soc Med, July 1, 2007; 100(7): 339 - 340.
[Full Text] [PDF]


Home page
Hum ReprodHome page
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S
Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial
Hum. Reprod., February 1, 2007; 22(2): 500 - 505.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Lindeberg, K. Carlstrom, O. Ritvos, and O. Hovatta
Gonadotrophin stimulation of non-luteinized granulosa cells increases steroid production and the expression of enzymes involved in estrogen and progesterone synthesis
Hum. Reprod., February 1, 2007; 22(2): 401 - 406.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Gomez, M. Gonzalez-Izquierdo, R. C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer
Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model
Endocrinology, November 1, 2006; 147(11): 5400 - 5411.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
N. G M Beckers, P. Platteau, M. J Eijkemans, N. S Macklon, F. H de Jong, P. Devroey, and B. C J M Fauser
The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women.
Eur. J. Endocrinol., August 1, 2006; 155(2): 355 - 363.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen
GnRH antagonists in ovarian stimulation for IVF
Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. F. Costello, M. Chapman, and U. Conway
A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome
Hum. Reprod., June 1, 2006; 21(6): 1387 - 1399.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva
Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial
Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
E.M.E.W. Heijnen, M.J.C. Eijkemans, E.G. Hughes, J.S.E. Laven, N.S. Macklon, and B.C.J.M. Fauser
A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome
Hum. Reprod. Update, January 1, 2006; 12(1): 13 - 21.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Y. Ng, O. S. Tang, C. C. W. Chan, and P. C. Ho
Ovarian stromal blood flow in the prediction of ovarian response during in vitro fertilization treatment
Hum. Reprod., November 1, 2005; 20(11): 3147 - 3151.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Y. Ng, C. C. W. Chan, W. S. B. Yeung, and P. C. Ho
Comparison of ovarian stromal blood flow between fertile women with normal ovaries and infertile women with polycystic ovary syndrome
Hum. Reprod., July 1, 2005; 20(7): 1881 - 1886.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Y. Ng, C. C. W. Chan, O. S. Tang, and P. C. Ho
Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment
Hum. Reprod., June 1, 2005; 20(6): 1647 - 1654.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E. J P van Santbrink, F. P Hohmann, M. J C Eijkemans, J. S E Laven, and B. C J M Fauser
Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment
Eur. J. Endocrinol., April 1, 2005; 152(4): 611 - 617.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. G. Papanikolaou, H. Tournaye, W. Verpoest, M. Camus, V. Vernaeve, A. Van Steirteghem, and P. Devroey
Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile
Hum. Reprod., March 1, 2005; 20(3): 636 - 641.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Daelemans, G. Smits, V. de Maertelaer, S. Costagliola, Y. Englert, G. Vassart, and A. Delbaere
Prediction of Severity of Symptoms in Iatrogenic Ovarian Hyperstimulation Syndrome by Follicle-Stimulating Hormone Receptor Ser680Asn Polymorphism
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6310 - 6315.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Delbaere, G. Smits, O. Olatunbosun, R. Pierson, G. Vassart, and S. Costagliola
New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?
Hum. Reprod., March 1, 2004; 19(3): 486 - 489.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.